EQS-News: APONTIS PHARMA launches Single Pill Finder and distribution of Single Pill Rosazimib - First of three launches in 2023

APONTIS PHARMA launches Single Pill Finder and distribution of Single Pill Rosazimib - First of three launches in 2023
 

• Single Pill Finder online application shows real-time options to simplify therapy
• Free-of-charge physician assistance system for convenient continuation of loose combination as Single Pill
• New Single Pill Rosazimib on the market
• Further Single Pills to be marketed in 2023

Monheim, 29 June 2023. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, extends the distribution capabilities for Single Pills and the portfolio of already approved products. As such, the previously announced Single Pill Finder is available as of now. The online-based application enables physicians to selectively replace loose combinations (single drugs) with Single Pills according to the indication. Single Pills combine the established active ingredients in a single tablet in a daily single dose compared to loose combination therapy. The reduced number of tablets can increase adherence and thus contribute to improving prognosis, as demonstrated in the retrospective START and START 2.0 studies and the prospective SECURE study, among others. In addition, the new Single Pill Rosazimib is now available on the market, bringing the portfolio of already approved products in Germany to 11 Single Pills.

Single Pill Finder for regular use in the daily practice routine

As an online physician assistance system, the free-of-charge Single Pill Finder shows possible Single Pill options for simplifying therapy for patients on polymedication. Based on the existing nationally standardized medication plan for loosely combined preparations, the physician receives real-time recommendations for substitution with Single Pills. The medication plan can be entered in manually, as a photo or uploaded as a scan via desktop, tablet, or smartphone. The results are presented in a smart sort order according to the degree to which the therapy can be simplified, e.g., the proportion of single tablet substitutions. This makes it much easier for physicians to access solutions for simplifying therapies. The development for use under practice conditions was carried out with the participation of more than 400 physicians in Germany, according to the motto "by physicians for physicians."

Karlheinz Gast, Chief Executive Officer of APONTIS PHARMA AG: We are very pleased to expand our sales capabilities with the launch of the Single Pill Finder. With its easy use and the simplification of therapy that is visible in real time, we are providing physicians with a practical tool to increase adherence to therapy and improve the prognosis of their patients. In doing so, we are making a further contribution to establishing Single Pill as Gold Standard.

Launch of new Single Pill Rosazimib

Rosazimib (AP - D01) continues APONTIS PHARMA's announced Single Pill portfolio expansion, providing substitution therapy for the loose combination of Rosuvastatin and Ezetimibe. Launched on 28 June 2023, indications include primary hypercholesterolemia/homozygous familial hypercholesterolemia (HoFH) and prevention of cardiovascular events in patients with a history of coronary artery disease (CAD) and acute coronary syndrome. For the German market alone, APONTIS PHARMA anticipates annual sales potential of more than EUR 3.0 million in the medium term. In Germany, around 100,000 people are currently taking a loose combination of the two active ingredients contained in the new Single Pill.

Thomas Milz, Chief Product Officer (CPO) of APONTIS PHARMA AG: With Rosazimib, APONTIS PHARMA has launched the first of at least three Single Pills announced for 2023. At least two more Single Pills will be added this year, and the corresponding in-licensing has already taken place. In total, we now already have 11 Single Pills in the German market. The continuous launches not only successively expand our revenue streams, but also gradually reduce our dependence on individual products.

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form administered once a day. APONTIS PHARMA develops, promotes, and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS PHARMA successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europes leading pharmaceutical and chemical regions. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 25,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
apontis-pharma.com

APONTIS PHARMA Press Contact

CROSS ALLIANCE communication GmbH
Sven Pauly
ir@apontis-pharma.de
T: +49 89 125 09 0330